53 results about "Fat accumulation" patented technology

Provided is a novel Lactobacillus fermentum strain (Accession No. KCTC 14106BP) and a composition for preventing or treating a metabolic disease including the same. A Lactobacillus fermentum according to the present invention may inhibit fat accumulation and increase anti-inflammatory cells in white adipose tissue. In addition, the Lactobacillus fermentum may effectively inhibit fat accumulation in brown adipose tissue and in liver tissue. The Lactobacillus fermentum strain may exhibit excellent blood glucose improvement effect, and in particular, may reduce a fasting blood glucose level. The Lactobacillus fermentum strain may effectively ameliorate insulin resistance by improving glucose tolerance and increasing insulin sensitivity. Therefore, the Lactobacillus fermentum strain may be usefully used to prevent or treat a metabolic disease such as obesity.

The application discloses a construction method of a fat-targeted gene therapy vector. The method comprises the following steps: obtaining a fat tissue-specific promoter sequence; obtaining a shRNA coding sequence targeting a Tks4 gene; cloning the promoter sequence and the shRNA coding sequence into an adeno-associated virus vector skeleton to construct a recombinant expression vector; and co-transfecting the recombinant expression vector and an auxiliary plasmid into a packaging cell to package and purify a recombinant adeno-associated virus particle. The vector constructed by the application adopts an adiponectin promoter to drive the expression of miR30-shRNA targeting the Tks4, and can be specifically expressed in fat tissues and livers after being injected through a tail vein, significantly inhibits fat cell hypertrophy and systemic fat accumulation induced by a high-fat diet, reduces the serum cholesterol level, does not cause an immune inflammatory reaction, does not affect sugar metabolism, and is not expressed in non-target tissues. The application provides a safe and efficient new strategy for the gene therapy of obesity, hyperlipidemia, fatty liver and related metabolic diseases.

The present invention addresses the problem of defining physiological significance and functions such as the influence of nicotinamide mononucleotide (NMN) contained in breast milk on the development of children. A composition for improving the athletic ability of a child is provided comprising a precursor of NAD. The improvement in athletic ability is preferably any one selected from the group consisting of promotion of skeletal muscle development and improvement in activity. A composition for reducing triglyceride levels in the blood of a child is provided comprising a precursor of NAD. A composition for reducing the blood glucose level in a child is provided comprising a precursor of NAD. A composition for inhibiting fat accumulation in children is provided, comprising a precursor of NAD.

The invention discloses a pediococcus pentosaceus MDL511, which is preserved in the China General Microbiological Culture Collection Center (CGMCC), the preservation number is CGMCC No.35201, the preservation date is July 11, 2025, and the classification name of the strain is pediococcus pentosaceus. The pediococcus pentosaceus MDL511 has the advantages that the preservation number is CGMCC No.35201, the preservation number is CGMCC No.35201, the preservation date is July 11, 2025, and the classification name of the strain is pediococcus pentosaceus. The pediococcus pentosaceus MDL511 disclosed by the invention can be used for remarkably reducing weight gain and fat growth of mice caused by high fat diet, reducing serum cholesterol, LDL-C (Low Density Lipoprotein Cholesterol) and ALT (Atomic Lymphocyte Transferase) levels and remarkably improving hepatic lesions and fat accumulation caused by high fat diet, so that the MDL511 has a blood fat reducing effect, can be used for preparing blood fat reducing products and weight losing products and has a good development prospect.

The invention aims to provide a peptide for accelerating fat metabolism and application thereof, the peptide is prepared into a product convenient to use, and the amino acid sequence of the peptide is MVHSYSETSD. The peptide is obtained through peptide library screening, bioinformatics analysis screening and fat cell decomposition experiment verification, and it is verified that the active peptide obtained through screening has the effects of accelerating fat metabolism, inhibiting fat accumulation, reducing blood fat and body fat content and reducing body weight; the insulin sensitivity and the glucose tolerance are improved, and the prevention and treatment effects on obesity and complications thereof are realized.

The application aims to provide a peptide for accelerating fat metabolism and application thereof, and to prepare the peptide into a product convenient to use, and the amino acid sequence of the peptide is MVHSYSETSD. The peptide is obtained through screening of a peptide library, screening through bioinformatics analysis, and verification through fat cell decomposition experiment, and the application verifies that the active peptide screened has the effect of accelerating fat metabolism, inhibiting fat accumulation, reducing blood fat and body fat content, reducing body weight, improving insulin sensitivity and glucose tolerance, and realizing the prevention and treatment effect on obesity and its complications.

The present invention provides a composition for alleviating fatty liver disease by using a single or complex extract of Sigesbeckia glabrescens and Luffa cylindrica, the composition exhibiting the activities of inhibiting fat accumulation and inflammation in liver cells without showing toxicity to liver cells, inhibiting fat accumulation and inflammation in liver tissue in high-fat-diet animal models, and increasing the expression of glutathione, which is a strong antioxidant in liver tissue.

The invention relates to the technical field of medicines, in particular to application of an integrin beta3 inhibitor RGDfK in preparation of a medicine for treating metabolic dysfunction related fatty liver diseases. The RGDfK provided by the invention can inhibit palmitoylation and membrane localization of CD36 in liver tissues of mice with fatty liver diseases related to metabolic dysfunction induced by high fat diet feeding, so that lipid uptake of the liver is inhibited. Experimental results show that RGDfK can improve obesity and insulin resistance of mice with metabolic dysfunction-related fatty liver diseases, can improve fat accumulation, fibrosis and inflammatory infiltration of liver tissues of the mice with fatty liver diseases, and is expected to become a new medicine for treating the metabolic dysfunction-related fatty liver diseases.

1. The name of the design product: anti-fat accumulation instrument. 2. The use of the design product: the design product is used for cosmetic instrument of massage, anti-fat accumulation and anti-wrinkle treatment. 3. The design points of the design product: in shape. 4. The picture or photo that can best show the design points: perspective view.

This document describes the crystalline and liquid crystalline forms of sodium 25HC3S. This disclosure includes sodium 25HC3S in forms I, II, III, V, IX, XI, and XIII, and combinations thereof. Pharmaceutical formulations of the said forms or combinations thereof are further disclosed herein, as well as methods for treating or preventing diseases such as hypercholesterolemia, hypertriglyceridemia, and conditions associated with fat accumulation and inflammation (e.g., non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), alcoholic hepatitis, acute kidney injury (AKI), psoriasis, and atherosclerosis). Methods for preparing 25HC3S are also provided.

The use of a postbiotic of Bifidobacterium brevis 207-1 (GDMCC No. 60962) or a composition containing the postbiotic in the preparation of a medicine or a food product. The medicine or food product is used for preventing and / or ameliorating diseases and / or symptoms related to fat gain in a subject. The diseases and / or symptoms are selected from weight gain, obesity, fatty liver, fat accumulation (e.g., visceral fat accumulation and subcutaneous fat accumulation), abnormal lipid metabolism, or any combination thereof. The medicine or food product can promote the fat breakdown and / or inhibit the fat absorption, maintain or reduce the body weight and / or BMI of the subject, increase the satiety of the subject, and reduce the food intake of the subject.

A biological function modifier, comprising fermented collagen peptides, said fermented collagen peptides having at least one effect selected from the group consisting of promoting epidermal metabolism, inhibiting fat accumulation, promoting fat breakdown, and regulating the amount of adipokines in the body.

The invention relates to the field of daily chemicals, and discloses a composite massage preparation as well as a preparation method and application thereof. The preparation is prepared by compounding recombinant human-derived III-type collagen, a high-activity pollen protein extract and traditional Chinese medicine herbal essence according to a specific proportion, the traditional Chinese medicine herbal essence is prepared by extracting and purifying 12 medicinal materials, and the contents of alkaloid, flavonoid and polysaccharide are respectively greater than or equal to 12%, 18% and 15%. The preparation technology comprises the following steps: preparing recombinant collagen through genetic engineering, extracting pollen protein through supercritical CO2, and carrying out low-temperature dynamic cycle extraction and molecular distillation purification on traditional Chinese medicine components. The preparation has a remarkable synergistic effect by promoting lipolysis, repairing skin injury and regulating the body state, and in-vitro, animal and human body tests prove that the preparation has excellent effects in the aspects of reducing fat accumulation, improving skin elasticity and assisting metabolism regulation. The composition can be prepared into various dosage forms, is used for shaping the body, beautifying the skin and conditioning sub-health, and is comprehensive in effect, high in safety and wide in market prospect.

A patent obtained in the earlier stage is that the line peptide COX52-69 is cyclized to realize an oral administration route. The invention finds that the cyclic peptide has the effect of reducing body weight. The invention is named as application of the polypeptide COX52-69 in reducing liver fat accumulation and fat cell volume. In the invention, a diet-induced obesity (DIO) model is established by feeding C57BL / 6J mice with high-fat feed (45% of fat for energy supply) for 14 weeks. After a DIO mouse is obtained, a 17-week administration experiment is carried out by using a PBS buffer solution and a Rybelsus solution as a contrast, and observation finds that the COX52-69 cyclic peptide can reduce liver fat accumulation and reduce the fat cell volume of fat tissue while reducing the weight of the DIO mouse. Therefore, the COX52-69 cyclic peptide has practical application in improving the volume of the fatty liver and the fat cells.

The invention relates to application of a fingered citron extract in preparation of a medicine for treating metabolic syndrome, and belongs to the technical field of biological medicines. According to the fingered citron extract disclosed by the invention, the diversity of flora can be improved by regulating intestinal flora, and the relative abundance of beneficial bacteria Akkermansia is specifically increased, so that the metabolic syndrome induced by high fat diet is relieved. An embodiment verifies that the scheme of the invention not only can significantly inhibit weight gain of obese mice induced by high fat diet, improve glucose metabolism disorder (including reduction of fasting blood-glucose and improvement of oral glucose tolerance), relieve liver fat accumulation and pathological damage, reduce visceral fat accumulation and improve adipocyte hypertrophy, but also can significantly inhibit the weight gain of the obese mice induced by high fat diet and improve the glucose metabolism disorder (including reduction of fasting blood-glucose and improvement of oral glucose tolerance). And obesity-related metabolic hormone disorder can be effectively reversed, for example, the serum insulin level is improved, and the leptin level is reduced.

The disclosure is a peptide (Iaká (SEQ ID No1) with lightening action for periorbital hyperpigmentation, cosmetic or dermopharmaceutic composition containing this peptide and the use of this composition in the treatment of dark circles. Periorbital hyperpigmentation is a condition that does not add any risks to the patient's health state, however, it can cause aesthetic discomforts and appearance of tiredness. Dark circles can be formed due to anatomy or fat accumulation; due to a very thin skin thickness, allowing visualization of subcutaneous vessels; and, furthermore, due to melanin accumulation in the region. Due to this disclosure being a cosmetic composition, of topic non-invasive application, it can be applied daily without the requirement for an aesthetic specialist, besides not being as expensive as the currently known techniques for dark circles treatment. The peptide acts inhibiting melanogenesis.

The present invention relates to an anti-obesity composition comprising an extract of Rosa rugosa flower buds as an active ingredient, and by virtue of comprising the extract, aims to provide a composition having excellent anti-obesity efficacy by exhibiting the effects of inhibiting fat accumulation, reducing triglyceride content, increasing the expression of adipose triglyceride lipase (ATGL) and AMP-activated protein kinase (AMPK) proteins, and decreasing the expression of G0S2 (G0 / G1 switch 2) and perilipin proteins.

The present invention relates to the Bacteroides eggerthii KGMB05336 strain and a use thereof, wherein, through the analysis of the microbiome in patients with non-alcoholic fatty liver disease that is caused by obesity, the Bacteroides eggerthii strain was identified as a significant strain. Oral administration of the Bacteroides eggerthii strain to animal models of obesity and non-alcoholic fatty liver disease caused by obesity resulted in body weight reduction, liver weight reduction, decrease of fat accumulation in visceral and liver tissues, and reduction in serum levels of AST (U / L), ALT (U / L), cholesterol (mg / dL), and glucose (mg / dL), thus demonstrating that the Bacteroides eggerthii strain can serve as a novel means for the prevention, improvement, or treatment of obesity and diseases caused by obesity, such as fatty liver, hepatomegaly, non-alcoholic fatty liver disease, and diabetes.

The invention discloses a composition helpful for controlling in-vivo fat and application thereof, and relates to the technical field of biology. The hesperidin composition is prepared from hesperidin and lactobacillus johnsonii (Lactobacillus johnsonii), and the hesperidin composition is prepared from the hesperidin and the lactobacillus johnsonii. Research finds that the composition can achieve synergistic up-regulation of gene and protein expression of adipose tissue PGC1alpha and UCP1 and increase the body surface temperature; the composition can also significantly improve the bioavailability of hesperidin and improve the concentration of hesperetin and other metabolites in serum; the composition can also optimize the intestinal microecology, improve the intestinal flora structure, increase the lactobacillus colonization rate, enrich the abundance of beneficial bacteria and promote the generation of short-chain fatty acids; the composition can also significantly improve lipid metabolism disorder of an organism, reduce fat accumulation, regulate adiponectin and leptin levels, control fat in the body and realize effective weight loss management.

This cell line is derived from a fish belonging to the family Anguillidae, expresses at least one selected from the group consisting of vimentin, CD29, CD73, and CD105, and has ability to accumulate fat. Also provided is a method for producing cells in which fat accumulates, the method involving a step for culturing the cell line derived from a fish belonging to the family Anguillidae in a culture medium, and causing fat to accumulate in the cells. Also provided is a fat production kit comprising the cell line derived from a fish belonging to the family Anguillidae, a fat accumulation culture medium, and a culture container.

The invention provides a single-component self-crosslinking hydrogel as well as a preparation method and application thereof in weight management. The hydrogel only contains one component sodium carboxymethyl cellulose, a cross-linking agent does not need to be introduced, a single component is self-crosslinked, washing is not needed, the preparation method is simple, and the preparation cost can be effectively reduced. The hydrogel has a porous structure, has extremely high water absorption swelling capacity and elasticity modulus in the stomach and intestine, generates continuous satiety and reduces intake of heat. The sodium carboxymethyl cellulose serving as dietary fiber can also absorb fat in intestinal tracts, and fat accumulation can be reduced. The gel disclosed by the invention can also avoid the risk that the stomach enters the small intestine to be blocked after being emptied. The compound can be used for preparing food, health care products or medical instruments for preventing or treating overweight or obesity and endocrine diseases caused by obesity.

The present disclosure relates to the field of microbial therapy, and specifically to a product for preventing and / or treating obesity and a metabolic syndrome. The product includes a Lactobacillus acidophilus strain JYLA-126 and a coating solution thereof. A bacterial solution of the L. acidophilus strain JYLA-126 is coated with a bacterial coating solution to better transport the bacterial solution to the intestinal tract to exert therapeutic effects. The L. acidophilus strain JYLA-126 coating solution is used for intragastric treatment of obesity mice induced by high-fat diet. Various indicators show that the L. acidophilus strain JYLA-126 coating solution may effectively regulate intestinal microflora and maintain intestinal health. The coating solution improves liver glucose metabolism, reduces liver oxidative stress, improves liver lipid metabolism, and alleviates a liver inflammation level. This coating solution improves white adipose accumulation and promotes brown adipose thermogenesis, thereby achieving effective treatment of obesity and metabolic syndrome in mice.

The present invention relates to a nutraceutical composition for the prevention and / or treatment of obesity and / or overweight and / or the yo-yo effect in humans or animals, comprising a mixture of extracts of Chrysanthellum americanum and Hibiscus sabdariffa, or a single extract obtained from these two plants. The combination of these extracts allows for a synergistic effect that improves efficacy in regulating lipid metabolism and reducing fat accumulation in preadipocytes. Figure for the abstract: Fig. 1

The invention provides 3, 5-substituted imidazo-thiadiazole heterocyclic derivatives as well as a preparation method and application thereof, in particular, a series of 3, 5-substituted imidazo-thiadiazole heterocyclic derivatives are obtained through screening, and the 3, 5-substituted imidazo-thiadiazole heterocyclic derivatives can inhibit eIF4E phosphorylation, reduce generation of p-eIF4E, reduce weight gain, relieve fat accumulation, relieve inflammation and other changes, improve the activity of the 3, 5-substituted imidazo-thiadiazole heterocyclic derivatives and improve the activity of the 3, 5-substituted imidazo-thiadiazole heterocyclic derivatives. The invention also relates to the application of the compound in drugs for preventing and / or treating metabolic diseases, thrombotic diseases, sepsis acute kidney injury, MASLD (Metabolic Fatty Liver Disease), MASH (Metabolic Steatohepatitis) and the like related to eIF4E phosphorylation level imbalance. The metabolic diseases related to eIF4E phosphorylation level imbalance are selected from type 1 diabetes mellitus, type 2 diabetes mellitus, hyperlipidemia, obesity, fatty liver diseases, complications thereof and diseases related to the complications.

This invention provides peptides with anti-obesity and / or anti-diabetic activity, composed of the amino acid sequence of Sequence 1 or Sequence 2. These peptides inhibit fat accumulation, reduce the size of adipocytes, and increase the expression of phosphorylated hormone-sensitive lipase, adenosine monophosphate-activated protein kinase-α1, and comparative gene recognition-58 (CGM-58), which are lipolysis factors, thereby breaking down accumulated fat. This not only exhibits excellent anti-obesity effects but also effectively reduces blood glucose levels, increasing the expression of adiponectin and adenosine monophosphate-activated protein kinase (CGM-58), which improve insulin resistance; increasing the expression of glucose transporter protein 4 (a glucose transport channel); and increasing the expression of insulin receptor substrate-1 (an insulin receptor signaling protein), thus exhibiting excellent effects against diabetes. The peptides of this invention can be effectively used in the prevention or treatment of obesity and / or diabetes.

The invention discloses a slimming polypeptide and application thereof in directional lipolysis, the slimming polypeptide has human-derived specific lipolysis activity, can specifically recognize and dissolve white adipocytes of a human body, and has amino acid sequences as shown in SEQ ID NO: 1-SEQ ID NO: 3. The slimming polypeptide disclosed by the invention has human-derived specific fat-dissolving activity, and can be used for accurately targeting white fat cells of a human body and effectively dissolving fat accumulation. The slimming polypeptide can be used in the fields of cosmetics and medicines, has the characteristics of human-derived specific fat dissolving activity, high efficiency and safety, and can effectively reduce fat accumulation and realize directional slimming.

The invention belongs to the technical field of biological medicines, and discloses a novel application of an epimedium aqueous extract, icariin and icaritin in improvement of senescence-related fat accumulation and redistribution. The invention constructs a nematode-mouse dual verification model: firstly, in a caenorhabditis elegans model, it is found that the active ingredients can significantly reduce fat droplet accumulation and triglyceride level in senescence nematode bodies, and especially under the concentration of 50 [mu] M, icariin can reduce the triglyceride content of 15-day-old senescence nematode to 37.58% of a control group. Furthermore, a naturally aged mouse is evaluated by utilizing a high-resolution Micro-CT (VivaCT 80) living body imaging technology, and three-dimensional reconstruction and quantitative analysis prove that the medicine can remarkably reduce the volume of visceral fat in the abdomen of the aged mouse, effectively improve the ratio of visceral fat to subcutaneous fat (VAT / SAT ratio) and reverse central obesity caused by aging. The raw materials are from natural plants, have no obvious toxic or side effect after long-term administration, can accurately improve fat space distribution of aging organisms, and have significant clinical application value.

The present application provides use of Monascinol in preparation of a fat-reducing product, a method for preventing or treating a disease related to abnormal lipid metabolism, and a fat-reducing product including Monascinol. The fat-reducing product includes a fat-reducing functional food and a fat-reducing drug, the fat-reducing functional food is used for preventing or improving a sub-health state related to obesity in an individual, the fat-reducing drug is used for preventing or treating a disease related to abnormal lipid metabolism in an individual. It is found that in the solution of the present application the Monascinol has new functions of significantly lowering blood lipid, controlling weight gain, and inhibiting body fat accumulation; and has low cytotoxicity, thereby having high use safety when serving as a fat-reducing product.

The present invention aims to provide a food (including foods for specified health uses and foods with functional claims) or pharmaceutical product containing rare sugars as an active ingredient that can be used for novel applications. [Solution] The above problem is achieved by a food composition or pharmaceutical composition containing D-allose, D-sorbose, or derivatives thereof as an active ingredient, for the prevention, improvement, or treatment of symptoms or diseases selected from the group consisting of obesity due to overeating, diabetes or elevated blood glucose levels resulting from obesity due to overeating, and hepatic fat accumulation resulting from obesity due to overeating.